Drug intelligence / Profile preview

Fluzone High-Dose + Nuvaxovid

Development stage: Preclinical
Lead developer: Sanofi
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Fluzone High-Dose + Nuvaxovid is a combination vaccine under development, designed to provide protection against both influenza and COVID-19. It combines Sanofi's high-dose influenza vaccine, Fluzone High-Dose, with Novavax's protein-based COVID-19 vaccine, Nuvaxovid. Nuvaxovid utilizes Novavax's proprietary Matrix-M adjuvant technology to enhance the immune response. Sanofi has licensed rights from Novavax to co-commercialize Nuvaxovid and to develop new combination vaccines incorporating Novavax's adjuvant technology.

Brand names: Fluzone High-Dose
Other names: Seasonal influenza virus vaccine high dose + COVID-19 Vaccine, adjuvanted

Targets

SARS-CoV-2 spikeHA (Hemagglutinin)

Beyond the preview

Go deeper on Fluzone High-Dose + Nuvaxovid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fluzone High-Dose + Nuvaxovid.

Explore the full profile